PATENT CLAIM ANALYSIS

Application Number: 15956434
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["546", "275400"]

Abstract:
The present embodiments relate to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signalling, such as inflammatory disorders, cancer and neoplastic disease. Particular compounds described herein exhibit selective inhibitory activity against CBP compared with BRD4.

Claim (Index 57):
The compound of  claim 4 , wherein R 1  is optionally substituted cyclyl.

Metadata:
- Claim Count in Document: 43.0
- Percentile: 91.0
- Lexical Diversity: 1.4
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15488674', '14361171', '12411956', '10899458', '13825665']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8304780397147402
- 35 USC 102 Novelty (BERT): 0.5391976063554637
- Combined Prediction Score: 0.8013499963788125
- Mean Citation Score: 374.99574999999993
- Max Citation Score: 403.73682
- Similarity Product: 267.82343432674173

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test